TY  - JOUR
PY  - 2014//
TI  - Pharmacotherapy of Traumatic Brain Injury: State of the Science and the Road Forward Report of the Department of Defense Neurotrauma Pharmacology Workgroup
JO  - Journal of neurotrauma
A1  - Diaz-Arrastia, Ramon
A1  - Kochanek, Patrick Michael
A1  - Bergold, Peter
A1  - Kenney, Kimbra
A1  - Marx, Christine
A1  - Grimes, Jamie B.
A1  - Loh, Yince
A1  - Adam, Gina
A1  - Oskvig, Devon Brost
A1  - Curley, Kenneth C.
A1  - Salzer, Wanda
SP  - 135
EP  - 158
VL  - 31
IS  - 2
N2  - Despite substantial investments by government, philanthropic, and commercial sources over the past several decades, traumatic brain injury (TBI) remains an unmet medical need and a major source of disability and mortality in both developed and developing societies. The U.S. Department of Defense neurotrauma research portfolio contains more than 500 research projects funded at over $700 million, and is aimed at developing interventions that mitigate the effects of trauma to the nervous system and lead to improved quality of life outcomes. A key area of this portfolio focuses on the need for effective pharmacologic approaches for treating patients with traumatic brain injury (TBI) and its associated symptoms. The Neurotrauma Pharmacology Workgroup was established by the U.S. Army Medical Research and Materiel Command (USAMRMC) with the overarching goal of providing a strategic research plan for developing pharmacologic treatments that improve clinical outcomes after TBI. To inform this plan, the Workgroup (a) assessed the current state of the science and ongoing research and (b) identified research gaps to inform future development of research priorities for the neurotrauma research portfolio. The Workgroup identified the six most critical research priority areas in the field of pharmacological treatment for individuals with TBI. The priority areas represent parallel efforts required to advance clinical care; each requires independent effort and sufficient investment. These priority areas will help the USAMRMC and other funding agencies strategically guide their research portfolios to ensure the development of effective pharmacologic approaches for treating patients with TBI.<p /> <p>Language: en</p>
LA  - en
SN  - 0897-7151
UR  - http://dx.doi.org/10.1089/neu.2013.3019
ID  - ref1
ER  -